Patent: 9,717,717
✉ Email this page to a colleague
Summary for Patent: 9,717,717
Title: | Methods of treating cancer through the inhibition of USP7 and immune system modulation |
Abstract: | Methods and compounds for treating cancer by, for example, modulating immune system activity, are provided. |
Inventor(s): | Weinstock; Joseph (Wayne, PA), Wu; Jian (Chester Springs, PA), Kizhakkethil-George; Suresh Kumar (Downingtown, PA), Wang; Feng (Devon, PA), Kodrasov; Matthew P. (Cherry Hill, NJ), Agarwal; Saket (Woburn, MA), Hancock; Wayne W. (Philadelphia, PA) |
Assignee: | Progenra, Inc. (Malvern, PA) The Children\'s Hospital of Philadelphia (Philadelphia, PA) |
Application Number: | 15/222,204 |
Patent Claims: | see list of patent claims |
Details for Patent 9,717,717
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2035-07-31 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2035-07-31 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2035-07-31 |
Genzyme Corporation | LEMTRADA | alemtuzumab | Injection | 103948 | 11/14/2014 | ⤷ Try a Trial | 2035-07-31 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 10/12/2004 | ⤷ Try a Trial | 2035-07-31 |
Merck Sharp & Dohme Corp. | GARDASIL | human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant | Injection | 125126 | 06/08/2006 | ⤷ Try a Trial | 2035-07-31 |
Dendreon Pharmaceuticals Llc | PROVENGE | sipuleucel-t | Injection | 125197 | 04/29/2010 | ⤷ Try a Trial | 2035-07-31 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |